In Australia around 2,400 people are diagnosed each year with multiple myeloma (MM), and around 20,000 patients are living with MM at any given time. Unfortunately, more than 1000 patients will die from this form of blood cancer in any given year and therefore new treatment options such as XPOVIO® are needed. Antengene Corporation Limited today announced that the Therapeutic Goods Administration (TGA) of the Australian Government Department of Health has registered XPOVIO® (selinexor) for two indications: (1) In […]
Click here to read: eTurboNews | TravelWireNews | TravelNewsOnline
Click here to read the full article.